Last reviewed · How we verify
NCT02893826
Multicenter, Controlled, Randomized, Safety and Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Phase 1 trial testing EG-1962 (nimodipine microparticles) in Subarachnoid Hemorrhage, Aneurysmal in 6 participants. Terminated before completion.
1 December 2017
Quick facts
| Lead sponsor | Edge Therapeutics Inc |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 1 September 2016 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 March 2018 |
| Sites | 4 locations across United States, Canada |
Drugs / interventions tested
- EG-1962 (nimodipine microparticles) — full drug profile →
- Enteral Nimodipine — full drug profile →
Conditions studied
- Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →
Sponsor
Edge Therapeutics Inc — full company profile →
Who can join
Adults 18 to 75, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Incidence and severity of adverse events
Time frame: 90 Days -
Proportion of subjects with delayed cerebral infarctions present on CT at Day 30
Time frame: 30 Days
Sponsor's own description
Safety and Pharmacokinetic study comparing intracisternal EG-1962 to enternal nimopidine in the treatment of aneurysmal subarachnoid hemorrhage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease.
De BP, Rosenberg JB, Selvan N, Wilson I, et al · · 2023 · cited 8× · PMID 37624739 · DOI 10.1089/hum.2023.067
Verify or expand the search:
- PubMed search for NCT02893826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal
Currently open trials in the same condition.
- NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
- NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
- NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
- NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
- NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02893826 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Edge Therapeutics Inc
- Last refreshed: 24 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02893826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing